Ambisome



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 60.1%
Drug Use For Unknown Indication 7.2%
Fungal Infection 5.3%
Bronchopulmonary Aspergillosis 4.2%
Visceral Leishmaniasis 3.1%
Aspergillosis 2.0%
Zygomycosis 1.9%
Prophylaxis 1.8%
Meningitis Cryptococcal 1.7%
Febrile Neutropenia 1.6%
Pneumonia 1.4%
Systemic Candida 1.4%
Acute Myeloid Leukaemia 1.3%
Sedation 1.2%
Candidiasis 1.0%
Systemic Mycosis 1.0%
Cryptococcosis 1.0%
Infection 1.0%
Pyrexia 0.9%
Sepsis 0.9%
Rhabdomyolysis 12.9%
Drug Ineffective 12.4%
Death 10.4%
Off Label Use 6.3%
Hypokalaemia 5.6%
White Blood Cell Count Decreased 5.4%
Renal Impairment 4.8%
Renal Failure 4.6%
Respiratory Failure 4.4%
Sepsis 4.4%
Renal Failure Acute 4.1%
Pyrexia 3.7%
Drug Ineffective For Unapproved Indication 3.2%
Pancytopenia 3.2%
Shock 2.9%
Renal Disorder 2.7%
Ventricular Fibrillation 2.4%
Vomiting 2.4%
Interstitial Lung Disease 2.0%
Tachycardia 2.0%
Secondary
Product Used For Unknown Indication 43.3%
Prophylaxis 7.2%
Drug Use For Unknown Indication 5.5%
Pneumonia 4.4%
Fungal Infection 3.7%
Infection 3.6%
Acute Myeloid Leukaemia 3.0%
Sedation 3.0%
Myelodysplastic Syndrome 2.9%
Ureteral Stent Insertion 2.8%
Ureteral Stent Removal 2.8%
Fluid Replacement 2.5%
Insomnia 2.2%
Sepsis 2.1%
Acute Lymphocytic Leukaemia 2.0%
Bronchopulmonary Aspergillosis 2.0%
Infection Prophylaxis 1.9%
Pyrexia 1.8%
Hypertension 1.8%
Febrile Neutropenia 1.6%
Renal Impairment 14.2%
Off Label Use 10.2%
Renal Failure 7.3%
Respiratory Failure 6.9%
Toxic Epidermal Necrolysis 6.9%
Renal Failure Acute 6.3%
Drug Ineffective 4.3%
Rhabdomyolysis 4.3%
Platelet Count Increased 4.0%
Pancreatitis Acute 3.6%
Thrombocytopenia 3.6%
Blood Alkaline Phosphatase Increased 3.3%
Cholestasis 3.3%
Hypokalaemia 3.3%
Renal Disorder 3.3%
Staphylococcal Infection 3.3%
Transfusion 3.3%
Vomiting 3.0%
Weight Increased 3.0%
Anaphylactic Reaction 2.6%
Concomitant
Product Used For Unknown Indication 21.3%
Drug Use For Unknown Indication 18.8%
Acute Myeloid Leukaemia 12.0%
Prophylaxis 8.5%
Infection 4.0%
Acute Lymphocytic Leukaemia 3.7%
Antifungal Prophylaxis 3.3%
Multiple Myeloma 3.3%
Nausea 2.9%
Febrile Neutropenia 2.7%
Myelodysplastic Syndrome 2.4%
Allogenic Bone Marrow Transplantation Therapy 2.3%
Bronchopulmonary Aspergillosis 2.2%
Sepsis 2.2%
Pneumonia 1.9%
Immunosuppression 1.9%
Hiv Infection 1.8%
Hypertension 1.8%
Infection Prophylaxis 1.6%
Fungal Infection 1.5%
Sepsis 13.9%
Thrombocytopenia 9.7%
Septic Shock 9.4%
Pneumonia 7.7%
White Blood Cell Count Decreased 7.1%
Renal Failure 5.8%
Pyrexia 5.2%
Venous Stent Insertion 5.2%
Vomiting 4.2%
Renal Impairment 3.9%
Febrile Neutropenia 3.5%
Respiratory Failure 3.2%
Venoocclusive Liver Disease 3.2%
Weight Increased 3.2%
Death 2.9%
Platelet Count Decreased 2.6%
Rectal Haemorrhage 2.6%
Tachycardia 2.6%
Renal Failure Acute 2.3%
Drug Ineffective 1.9%
Interacting
Product Used For Unknown Indication 59.9%
Zygomycosis 5.1%
Acute Promyelocytic Leukaemia 4.5%
Pulmonary Mycosis 4.5%
Hyperglycaemia 3.2%
Bacterial Infection 2.5%
Febrile Neutropenia 2.5%
Fungal Infection 2.5%
Neutrophil Count Decreased 2.5%
Pain 2.5%
Pneumonia 2.5%
Pneumonia Fungal 2.5%
Chronic Granulomatous Disease 1.3%
Prophylaxis Against Gastrointestinal Ulcer 1.3%
Type 1 Diabetes Mellitus 1.3%
Infection 0.6%
Tumour Associated Fever 0.6%
Torsade De Pointes 22.6%
Myoclonic Epilepsy 19.4%
Drug Interaction 16.1%
Hypokalaemia 12.9%
Myositis 6.5%
Pulmonary Haemorrhage 6.5%
Treatment Noncompliance 6.5%
Blood Creatinine Increased 3.2%
Cardiac Failure 3.2%
Hepatic Function Abnormal 3.2%